In our study, we demonstrate that one ubiquitin binding protein SHARPIN, which is correlated with ERα expression in clinical breast tumor samples, potentiates ERα signaling activity and promotes tamoxifen resistance through post-translational modifications. The gene discussed is SHARPIN; the disease is breast neoplasm.